ARISTOCORT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an injectable small-molecule corticosteroid approved in 1961 for systemic and localized inflammatory and allergic conditions. The exact mechanism involves glucocorticoid receptor binding to suppress immune and inflammatory responses. Specific indications are not detailed in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); team size and commercial investment likely declining as patent expiry nears.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal active hiring; working on ARISTOCORT offers limited career progression as the product transitions to LOE. Roles focus on defending market share and managing decline rather than growth and innovation.
Brand ManagerField Sales Representative
Worked on ARISTOCORT at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.